Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQP87H
|
|||
| Drug Name |
177-Lu-oxodotreotide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 3 | [1] | |
| Company |
Millburn
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor (SSTR) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01842165) 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (LUMEN). U.S. National Institutes of Health. | |||
| REF 2 | Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.